The sum was factored into the company’s sales and earnings outlook for the year, he said. Meanwhile, Pfizer expanded its ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable to predict at this time.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

(Reuters) -Pfizer said on ... LEANING ON COST SAVINGS The company said it now expects about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional ...

Pfizer on Tuesday reaffirmed its outlook for ... The company launched its multiyear cost-cutting plan in 2023 after the drugmaker miscalculated demand for its Covid-19 products.

(Reuters) -Pfizer said on Tuesday it would generate ... about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional $500 million in R&D savings ...